OncoGenex Pharmaceuticals Inc.
1522 217th Place SE
About OncoGenex Pharmaceuticals Inc.OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.
We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.
We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.
In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:
• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer; • a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and • a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.
We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.
Learn more about OncoGenex at www.oncogenex.com
US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500
Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678
Founders: Martin Gleave and Scott Daniel Cormack
CEO and Founder: Scott Cormack
CMO (Medical): Cindy Jacobs
CFO: John Bencich
Please click here for.
Please click here for clinical trial information.
Tweets by OncoGenex
208 articles with OncoGenex Pharmaceuticals Inc.
OncoGenex Pharmaceuticals Inc. Announces Custirsen Phase 3 "ENSPIRIT Trial Continues Following Completion Of Final Futility Survival Analysis
OncoGenex Pharmaceuticals Inc. Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis
OncoGenex Pharmaceuticals Inc. Announces Data From Borealis-1 Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
OncoGenex Pharmaceuticals Inc. Announces Share Purchase Agreement With Lincoln Park Capital Fund, LLC
OncoGenex Pharmaceuticals Inc. To Report Financial Results For Fourth Quarter And Year End 2014 On March 26, 2015
OncoGenex Pharmaceuticals Inc. And Sarah Cannon Research Institute Announce Completion Of Patient Enrollment In The Spruce Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small
OncoGenex Pharmaceuticals Inc. Announces Relocation Of Corporate Headquarters, Expected To Yield Savings Of At Least $4 Million Over Next Three Years
OncoGenex Pharmaceuticals Inc. Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
OncoGenex Pharmaceuticals Inc. Snags $27 Million and Prostate/Lung Cancer Rights From Teva Pharmaceutical Industries Limited
OncoGenex Pharmaceuticals Inc. Announces Results From The Phase 2 Borealis-1 Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer